Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyCUDC-907
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- CUDC-907
- Accession Number
- DB11891
- Type
- Small Molecule
- Groups
- Investigational
- Description
CUDC-907 has been used in trials studying the treatment of Lymphoma, Solid Tumors, BREAST CANCER, Multiple Myeloma, and NUT Midline Carcinoma, among others.
- Structure
Structure for DB11891 (CUDC-907)
- Synonyms
- Not Available
- External IDs
- CUDC907
- Categories
- UNII
- 3S9RX35S5X
- CAS number
- 1339928-25-4
- Weight
- Average: 508.56
Monoisotopic: 508.164122459 - Chemical Formula
- C23H24N8O4S
- InChI Key
- JOWXJLIFIIOYMS-UHFFFAOYSA-N
- InChI
- InChI=1S/C23H24N8O4S/c1-30(23-25-11-15(12-26-23)22(32)29-33)13-16-9-17-19(36-16)21(31-5-7-35-8-6-31)28-20(27-17)14-3-4-18(34-2)24-10-14/h3-4,9-12,33H,5-8,13H2,1-2H3,(H,29,32)
- IUPAC Name
- N-hydroxy-2-({[2-(6-methoxypyridin-3-yl)-4-(morpholin-4-yl)thieno[3,2-d]pyrimidin-6-yl]methyl}(methyl)amino)pyrimidine-5-carboxamide
- SMILES
- COC1=CC=C(C=N1)C1=NC(N2CCOCC2)=C2SC(CN(C)C3=NC=C(C=N3)C(=O)NO)=CC2=N1
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with CUDC-907. Approved - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Compound
- 54575456
- PubChem Substance
- 347828226
- ChemSpider
- 29314960
- BindingDB
- 50188961
- ChEMBL
- CHEMBL3622533
- Wikipedia
- Phosphoinositide_3-kinase_inhibitor
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Active Not Recruiting Treatment Malignant Lymphomas / Multiple Myeloma (MM) 1 1 Recruiting Treatment Cancer, Breast / High-grade Serous Ovarian Cancer / NUT Midline Carcinoma (NMC) / Triple-Negative Breast Cancer (TNBC) / Tumors, Solid 1 1 Recruiting Treatment Malignant Lymphomas / Neoplasms, Brain / Neuroblastomas / Tumors, Solid 1 2 Completed Treatment Differentiated Thyroid Cancer (DTC) / Neoplasms, Thyroid / Poorly Differentiated and Undifferentiated Thyroid Cancer 1 2 Recruiting Treatment Relapsed and/or Refractory Diffuse Large B-cell Lymphoma / Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0153 mg/mL ALOGPS logP 2.59 ALOGPS logP 2.78 ChemAxon logS -4.5 ALOGPS pKa (Strongest Acidic) 9.24 ChemAxon pKa (Strongest Basic) 3.36 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 11 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 138.72 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 145.82 m3·mol-1 ChemAxon Polarizability 53.01 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as pyridinylpyrimidines. These are compounds containing a pyridinylpyrimidine skeleton, which consists of a pyridine linked (not fused) to a pyrimidine by a bond.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazines
- Sub Class
- Pyrimidines and pyrimidine derivatives
- Direct Parent
- Pyridinylpyrimidines
- Alternative Parents
- Thienopyrimidines / Pyrimidinecarboxamides / 2,3,5-trisubstituted thiophenes / Dialkylarylamines / Alkyl aryl ethers / Aminopyrimidines and derivatives / Pyridines and derivatives / Morpholines / Imidolactams / Heteroaromatic compounds show 6 more
- Substituents
- Pyridinylpyrimidine / Thienopyrimidine / Pyrimidine-5-carboxylic acid or derivatives / Pyrimidinecarboxamide / Dialkylarylamine / 2,3,5-trisubstituted thiophene / Alkyl aryl ether / Aminopyrimidine / Morpholine / Oxazinane show 18 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Drug created on October 20, 2016 14:57 / Updated on July 02, 2018 19:29